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Abstract
Background: In the past decade, researchers have focused on developing new biomaterials for cancer therapy that combine
imaging and therapeutic agents. In our study, we use a new biocompatible and biodegradable polymer, termed poly(glycerol malate
co-dodecanedioate) (PGMD), for the synthesis of nanoparticles (NPs) and loading of near-infrared (NIR) dyes. IR820 was chosen
for the purpose of imaging and hyperthermia (HT). HT is currently used in clinical trials for cancer therapy in combination with
radiotherapy and chemotherapy. One of the potential problems of HT is that it can up-regulate hypoxia-inducible factor-1 (HIF-1)
expression and enhance vascular endothelial growth factor (VEGF) secretion.
Results: We explored cellular response after rapid, short-term and low thermal dose laser-IR820-PGMD NPs (laser/NPs) induced-
heating, and compared it to slow, long-term and high thermal dose heating by a cell incubator. The expression levels of the reactive
oxygen species (ROS), HIF-1 and VEGF following the two different modes of heating. The cytotoxicity of NPs after laser/NP HT
resulted in higher cell killing compared to incubator HT. The ROS level was highly elevated under incubator HT, but remained at
the baseline level under the laser/NP HT. Our results show that elevated ROS expression inside the cells could result in the promo-
tion of HIF-1 expression after incubator induced-HT. The VEGF secretion was also significantly enhanced compared to laser/NP
HT, possibly due to the promotion of HIF-1. In vitro cell imaging and in vivo healthy mice imaging showed that IR820-PGMD NPs
can be used for optical imaging.
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Conclusion: IR820-PGMD NPs were developed and used for both imaging and therapy purposes. Rapid and short-term laser/NP
HT, with a low thermal dose, does not up-regulate HIF-1 and VEGF expression, whereas slow and long term incubator HT, with a
high thermal dose, enhances the expression of both transcription factors.
Introduction
The synthesis and development of novel polymers and their use
for nanoparticle (NP) synthesis has been an important focus of
materials science research in the past decade. NPs delivery
systems are useful for in vivo applications because their small
size (≈100 nm) allows them to escape reticuloendothelial
system (RES) uptake, resulting in prolonged plasma circulation
times. Moreover, they are able to stabilize and protect their
cargo from degradation, including drugs and other types of
biomolecules [1,2]. NPs have also proven to be useful in over-
coming multidrug resistance (MDR) by preventing the direct
interaction of drug exporter pumps with their substrates once
encapsulated in NPs [3]. An additional advantage of NPs is that
they are passively targeted to tumor sites because of the
enhanced permeability and retention (EPR) effect. This effect
occurs as a result of a combination of factors, including
increased pore sizes of tumor vasculature, fast tumor angiogen-
esis from increased secretion of vascular endothelial growth
factor (VEGF), and poor lymphatic clearance from tumor sites
[4]. Because of these advantages, we synthesized a new formu-
lation of polymeric NPs for image-guided therapy based on the
polymer poly(glycerol malate co-dodecanedioate) (PGMD)
developed in our lab. The work described in this manuscript is
based on experiments completed as a partial fulfillment of the
requirements for Tingjun Lei’s PhD thesis [5]. Biocompatible
and biodegradable PGMD polymers were synthesized through
the thermal condensation method by mixing glycol, malic acid
and 1,12-dodecanedioic acid (DDA). Following the synthesis of
PGMD polymer, PGMD NPs were also successfully formu-
lated.
Optical imaging has several advantages over more traditional
imaging techniques (MRI, PET, CT, etc.), such as high spatial
resolution, real time imaging, and systems that are usually
smaller and less expensive. Near-infrared imaging dyes (wave-
length 700–900 nm) are promising for in vivo imaging because
light at these wavelengths has minimal absorption by tissue
[6,7]. Moreover, some NIR dyes such as indocyanine green
(ICG) can be used as both imaging agents and heat generators
due to their unique photothermal properties. However, ICG has
a plasma half-life of about 3 min and a poor stability in aqueous
solution, which complicates the timing of imaging and hyper-
thermia (HT) [8]. In our previous work, we investigated the
commercially available cyanine dye IR820 and proposed that it
could be an alternative for ICG. Our studies have shown
that IR820 can be used in lieu of ICG in imaging and hyper-
thermia applications. Three-minute laser exposure (power at
1440 J/cm2) with 5 µM IR820 or ICG can elevate the tempera-
ture of cell culture media from 37 °C to 42 °C or from 37 °C to
46 °C, respectively [9]. Despite the fact that IR820 has a lower
fluorescence yield and results in a lower temperature increase
after laser exposure compared to ICG, we have found that either
5 µM IR820 or ICG can be used successfully for in vitro and in
vivo optical imaging, and the increased temperature created by
IR820 laser exposure is still within the range (usually 41–45 °C)
needed for killing cancer cells. More importantly, IR820 has
improved in vitro and in vivo stability compared to ICG. The in
vitro IR820 degradation half-time is about twice that of ICG. In
vivo, the plasma distribution half-life of IR820 is about 15 min,
which is 5 times that of ICG; with an elimination half-life of
over 30 h for IR820 compared to approximately 2 h for ICG [8].
Based on these advantages we chose IR820 as our near-infrared
agent and we synthesized and characterized IR820-PGMD NPs
for cancer imaging and HT applications.
HT is used clinically as an adjuvant treatment with chemo-
therapy and radiotherapy. HT achieves therapeutic benefits by
damaging cancer cell proteins and structures as a result of an
increase in cell temperature. However, one of the potential
problems is that hypoxia-inducible factor-1 (HIF-1) could be
up-regulated by HT [10,11]. An overexpression of HIF-1 has
often been correlated to a poor therapeutic outcome, since
HIF-1 could circumvent the anticancer drug effect by protecting
cells from drug-induced apoptosis [12-14]. Moreover, tumor
angiogenesis occurs partly by activating the expression of
VEGF, which is partially regulated by HIF-1 [15-17]. Given the
importance of HIF-1, studies of the effect of HT on this protein
are very relevant for therapeutic HT applications in cancer.
Goyal et al. and Chandel et al. reported that elevated reactive
oxygen species (ROS) levels in cells stabilize HIF-1 expression
[18,19]. On the other hand, ROS was also reported to induce
mRNA accumulation for heat shock protein 70 (HSP70) [20],
which is able to minimize the effect of heat on cells during heat
exposure by inducing cells’ thermotolerance [21,22]. Our
previous study investigated the effect of HT on cancer cells in a
thermal dose-dependent manner, and the results showed that
HSP70 was inhibited by indocyanine green (ICG)-induced rapid
heating after exposure to laser, so that the thermal protective
mechanism of the cells was not initiated [23]. This was
compared to the increased expression of HSP70 under slower
but longer term heat accumulation by using a cell culture incu-
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Figure 1: Subcellular localization of free IR820 (A) and IR820-PGMD NPs (B) in SKOV-3 after 24-hour incubation. Scale bar represents 20 µm.
bator. The results indicated that the promotion of HSP70 was
minimized during rapid heating.
As mentioned before, ROS can activate the expression of
HSP70. The inhibition of HSP70 during rapid-rate and low
thermal dose heating could possibly mean the abolishment of
ROS generation, or abolishment of ROS-induced expression of
HSP70. It would be important to investigate if laser-IR820-
PGMD NP (laser/NP)-induced HT could result in ROS genera-
tion and trigger an overexpression of HIF-1. We hypothesized
that rapid, short-term and low-dose heat accumulation after
laser exposure to IR820-PGMD NPs within cancer cells will not
activate ROS production and trigger HIF-1 and VEGF expres-
sion. Whereas slow and long-term incubator HT, with high
thermal dose, will activate ROS production and result in the
promotion of HIF-1 and VEGF expression. The study of cell
killing and the cellular response of ROS, HIF-1 and VEGF
expression in cancer cells after laser exposure are very impor-
tant in determining the effect of the heating rate and the amount
of thermal dose in the treatment of cancer cells. We used incu-
bator-induced HT to mimic the application of whole-body HT,
since the heating process is slow, thus taking a fairly long time
to reach the targeted temperature (39–43 °C). Therefore, the
comparison between incubator HT and laser/NP HT may
provide important information on the effects of different modes
of HT used in cancer therapy.
In a previous publication, we described the in vivo pharmacoki-
netics and biodistribution of IR820-PGMD NPs [24]. The
present manuscript concentrates primarily on the in vitro
response of cancer cells after hyperthermia. Therefore, this
paper focuses not only on the cancer imaging and therapy capa-
bilities of IR820-PGMD NPs, but also on exploring the cellular
response following two different HT modes. We first investi-
gated the potential application of IR820-PGMD NPs on cancer
imaging and therapy and compared the therapeutic effect to
incubator HT. Next, we performed cell-based assays to study
ROS, HIF-1 and VEGF expression under these two different
heating methods.
Results
Characterization of the PGMD polymer and
IR820-PGMD NPs
The MW of PGMD polymers measured by GPC column is
around 3000 Da. The glass transitional temperature (Tg) is
measured to be approximately 42 °C, which is within the range
of the IR820 temperature increase after laser exposure. The
diameters of void PGMD NPs and IR820-PGMD NPs (see
dynamic light scattering (DLS) measurements in Figure S1,
Supporting Information File 1) are 90 ± 18.2 nm, and
108 ± 7.4 nm (mean ± SD) respectively. The shape and size of
IR820-PGMD NPs were also confirmed with scanning electron
microscopy (SEM) imaging (see SEM images in Supporting
Information File 1, Figure S2). Polydispersity (PDI) is
0.142 ± 0.007 (mean ± SD), zeta potential is −28.3 ± 6.4 mV
(mean ± SD), and the dye loading efficiency is 8.2 ± 0.6
(wt/wt %) (mean ± SD). These results were obtained from ten
different NP batches.
Subcellular localization
Figure 1 shows images of cells treated with 5 µM free IR820 or
0.05 mg/mL IR820-PGMD NPs (equivalent to 5 µM IR820),
and illustrates that the localization of the agents within the cells
is similar. Free IR820 is widely spread throughout the cyto-
plasm, most likely due to interaction with intracellular proteins
such as ligandin [25]. In the case of the NP formulation, IR820
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released from the NPs should exhibit identical behavior as free
IR820, whereas IR820 still within the NPs is expected to be
located in endosomes/lysosomes. Lysotracker Blue was used to
identify that PGMD NPs were taken up by the cells through an
endocytosis pathway (Supporting Information File 1, Figure
S5). Calculated image ratio values, R, from the fluorescence
microscope images show that the NP formulation produces a
higher intracellular fluorescence intensity (R = 3.75 ± 0.54)
(mean ± SD) than the free dye (R = 2.89 ± 0.23) (mean ± SD)
after 24 h of incubation, although the difference is not statisti-
cally significant, possibly due to the small sample size (n = 3
for each group).
HT thermal dose calculation
The temperature curves during 1 h incubator HT and 3 min
laser/NP HT are shown in Figure S3 and S4 (Supporting Infor-
mation File 1). A much slower temperature increase curve was
observed in incubator HT compared to the temperature increase
in laser/NP exposure. The thermal doses given in these two
treatments were calculated according to the CEM43 model
developed by Sapareto et al. [26] with a slight modification to
accommodate for the utilization at 42 °C (CEM42) with a
smaller empirical value R = 0.25. Laser/NP HT for 3 min with
5 µM IR820-PGMD NPs produced a much lower thermal dose
(CEM42 = 3.06 min) as compared to the 42 °C incubator HT
treatment (CEM42 = 25.98 min) over 1 h.
Cytotoxicity study
Our group previously described the thermal effects of IR820 in
cells exposed to 808 nm laser at a power density of 1440 J/cm2.
Specifically, exposure to 5 μM IR820 and a 3-minute laser
treatment under these conditions produces temperature
increases of 5 °C from a baseline of 37 °C [9]. Based on this
finding, we used a concentration of 0.05 mg/mL IR820-PGMD
NPs (containing approximately 5 μM IR820) in the current
study and compared it to the incubator treatment. Figure 2
shows the results of the cytotoxicity study in MES-SA and Dx5.
As seen in the figure, laser exposure without concomitant expo-
sure to IR820 did not significantly impact cell growth. It is also
noteworthy that NP concentrations equivalent to 5 µM IR820
had a slight cell growth inhibition effect on MES-SA cells. This
is in line with our previous observations on the cytotoxicity
effects of free IR820 on MES-SA, and seems to be related to
the fact that drug-sensitive MES-SA cells are more readily
affected by environmental changes and exposure to foreign
substances than their drug-resistant counterpart Dx5. Both incu-
bator HT and laser/NP-induced HT killed cancer cells due to
the HT effect (p < 0.05). Laser/NP HT cause greater cell
killing compared to incubator HT (p < 0.05), probably because
thermotolerance and cell protective mechanisms were not
triggered [27].
Figure 2: 24-hour cytotoxicity profile of IR820-PGMD NPs with laser
and incubator exposure in MES-SA and Dx5 cells; n = 3, 4 wells/treat-
ment. * p < 0.05 (by ANOVA) between laser/NP HT and incubator/NP
HT, indicating laser/NP HT results in significantly improved cytotoxicity
compared to incubator HT. ** p < 0.05 (by ANOVA) between HT and
without HT group in both cell lines, indicating significantly higher
cancer cell killing was achieved due to HT.
ROS production after HT treatment
ROS production after the two different modes of HT is shown
in Figure 3. Incubator HT at 42 °C for 1 h induced production
of ROS in both MES-SA and Dx5 cells, whereas ROS produc-
tion after 3 min of 5 μM laser/NP HT was not different from the
control cells that were incubated in a 37 °C incubator probably
because much less thermal dose was used, and/or the rapid
heating rate does not initiate the ROS production.
HIF-1 expression
As expected, incubator HT induced significantly elevated HIF-1
expression as compared to control (p < 0.05), while laser/NP
HT did not result in significant changes in HIF-1 expression as
shown in Figure 4. These results suggest that rapid laser/NP HT
did not up-regulate HIF-1 expression either as a result of the
rapid heating or low thermal dose or both.
VEGF expression
VEGF expression is shown in Figure 5. It is not surprising to
observe that VEGF secretion was enhanced after incubator HT,
since HIF-1 expression was elevated after incubator HT and
VEGF is one of the downstream target genes of HIF-1. Accord-
ingly, we did not observe significant changes in VEGF expres-
sion after laser/NP HT, given that laser/NP HT did not have any
effect on HIF-1 expression.
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Figure 3: HT-induced ROS production following laser/NPs and incu-
bator was measured in MES-SA and Dx5 cells. Fluorescent dye
CM-H2DCFDA was used to measure the fluorescence intensity and
normalized to values obtained from the control group (37 °C). *p < 0.05
indicates significant ROS production was observed in incubator
induced-HT as compared to control. Laser/NP induced-HT did not
result in enhanced ROS production as compared to control. Data
presented as mean ± SD, n = 3.
Figure 4: HT-induced HIF-1 expression after laser/NPs and incubator
was measured in MES-SA and Dx5 cells. HIF-1 activity was assayed
by using HIF-1 ELISA. All measured values were normalized to the
mean value of the treatment at 37 °C. * p < 0.05 indicates significant
HIF-1 expression was observed in incubator induced-HT as compared
to control. Laser/NP induced-HT did not result in promoted HIF-1
expression compared to control. Data presented as mean ± SD, n = 3.
In vivo imaging studies
In vivo imaging was performed for multiple time points as
described in the Experimental section. Images taken at 15 min
and 24 h are shown in Figure 6A and Figure 6B, respectively.
These images show that the biodistribution of IR820-PGMD
NPs is initially very similar to free IR820, as both were
processed rapidly through hepatobiliary excretion and start to
accumulate in the liver within the first 15 min. After 24 h, it
seems that both free dye and NPs were mainly located in the
Figure 5: HT-induced VEGF expression after laser/NP and incubator
was measured in MES-SA and Dx5 cells. VEGF secretion was
measured by using VEGF ELISA. The obtained VEGF expression
amount was normalized to SRB value as an indicator of cellular protein
amount. All the values measured were then normalized to the controls.
* p < 0.05 indicates significant VEGF expression was observed in incu-
bator HT as compared to control. Laser/NP HT did not result in
enhanced VEGF expression. Data presented as mean ± SD, n = 3.
liver. Our previous organ studies showed that considerable
IR820 content was also found in the kidneys and the lungs, indi-
cating uptake by RES [24]. However, the IR820 content in
kidneys and lungs is lower with NP formulation than in their
free form, possibly indicating less RES uptake of NPs, espe-
cially in the case of the kidneys. These differences were not
statistically significant, probably due to the small sample size
and individual variance. The NPs allow for longer image collec-
tion times. R values show that NPs have significantly higher
fluorescence intensity (R = 2.37 ± 0.70) (mean ± SD) than does
the dye in free form (R = 1.42 ± 0.19) (mean ± SD) 24 h after
injection (p < 0.05). Additionally, our previous pharmacoki-
netic analysis of plasma samples showed that IR820 plasma
concentration 24 h after injection was significantly higher when
administered in NP form compared to the free form [24]. Our
release kinetics and pharmacokinetics study results [24] seem to
indicate that the NP formulation stabilizes IR820, protecting it
from degradation and allowing for longer detection windows.
Discussion
The MW of PGMD polymer is 3000 Da, which is expected for
polymers synthesized by polycondensations of these MW
monomers of glycerol, malic acid and DDA [24,28]. The size of
the IR820-PGMD NPs is around 100 nm, which allows them to
escape RES uptake, and as a result, to have reduced plasma
clearance rates [2]. The loading of IR820 is equivalent to
5 µM IR820 in 0.05 mg/mL IR820-PGMD NPs, which is suffi-
cient to induce HT. IR820 is amphiphilic and has both
hydrophilic and hydrophobic properties, whereas PGMD is
hydrophobic. Therefore, there are hydrophobic-hydrophobic
Beilstein J. Nanotechnol. 2014, 5, 313–322.
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Figure 6: In vivo imaging of free IR820 and IR820-PGMD NPs. Figure 6A and 6B 15 min in vivo imaging. Figure 6C and 6D 24 h in vivo imaging.
interactions between IR820 and PGMD, and IR820 is encapsu-
lated inside the PGMD polymer matrix. Void PGMD NPs do
not have any cytotoxicity effect at this concentration. Optical
imaging of cancer cells and mice showed that the use of the NP
formulation resulted in a stronger fluorescence signal 24 h after
injection. This is consistent with the literature reporting that
nanoformulations can result in improved plasma circulation
time and protect the loading agent from degradation, which
would explain the higher intensities observed in vivo when
comparing the NP form with the free dye [29,30]. Our pharma-
cokinetics study showed that IR820-PGMD NPs administration
results in significantly increased IR820 plasma concentration
24 h after injection compared to free IR820. In addition, our
biodistribution studies showed that kidney IR820 dye content
was lower in NP form than in free IR820 form, which means
less IR820 was excreted through the renal system when in NP
form. This is consistent with kidney excretion being limited to
very small particles and small molecules.
The cytotoxicity studies showed that laser/NP induced HT
caused significantly higher cell killing than incubator HT,
although a much lower thermal dose was given to the cells. In
the commonly used CEM43 model for thermal dose calculation,
which normalizes the thermal dose to cumulative equivalent
minutes at 43 °C [26], the temperature and the duration of
heating can be used to define thermal damage. Our previous
paper and other groups’ reports indicate that the rate of
photothermal treatment might also affect the HT outcome,
because under rapid heating the cells are not able to initiate
protective mechanisms by inducing the expression of proteins
of the heat shock family to reduce DNA damage [23,31].
Although the laser/NP HT produced approximately 9 times less
thermal dose than incubator HT, it still resulted in significantly
higher cytotoxicity than incubator HT, thus confirming the
importance of the heating rate. Note that the final temperature
reached in both modes of HT was identical.
Madamanchi’s group reported that ROS can up-regulate HSP70
protein levels by binding signal transducers and activators of
transcription (STATs) to the HSP70 promoters in vascular
smooth muscle cells (VSMCs) [32]. This group exposed
VSMCs to H2O2 and found that the cytoplasmic janus tyrosine
kinase 2 (JAK2)/STAT pathway can up-regulate HSP70 and
minimize oxidative stress effects on the cells. The inhibition of
HSP70 expression under laser/NP HT probably means no
enhancement of ROS production within the cells. Our ROS
detection experiments support this hypothesis, showing that no
significant ROS was produced inside the cells after laser/NP HT
compared to controls. However, when incubator HT was used
to mimic conditions more similar to whole body HT, we
observed significant intracellular ROS production. This result is
consistent with Moon et al. reporting that ROS was activated
when a slow water bath HT was applied to cells. HT can acti-
vate the ERK pathway and increase NADPH oxidase activity,
which leads to the production of ROS [10]. Based on our
results, it seems that the application of rapid laser/NP HT to
cells will not induce an increase of ROS. However, the specific
mechanism of ROS abolishment within cells after laser/NP HT
has to be studied further.
Following the inhibition of ROS production in laser/NP HT
treatment, we did not observe enhanced HIF-1 expression.
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However, HIF-1 up-regulation was observed in slow and longer
term HT, probably because ROS production was activated in
the heating process. Other groups have also suggested that the
presence of ROS is able to up-regulate HIF-1 expression
[18,33]. HIF-1 is very important as a therapeutic target [34].
Traditional HT with slow and long-term heating appears benefi-
cial as an adjuvant therapy for radiotherapy and chemotherapy
since it can hinder DNA damage repair mechanisms and
increase drug delivery by enhancing its diffusion into the tumor
[35,36]. However, this heating modality is also able to induce
up-regulation of HIF-1, and the overexpression of HIF-1 could
compromise the therapeutic effect by increasing drug resistance
by an up-regulation of p-glycoprotein and by reducing cancer
cells drug senescence [37,38]. Our results showed that VEGF
secretion was also elevated along with the up-regulation of
HIF-1, which could potentially result in enhanced tumor angio-
genesis. The combination of HT and other therapies could
elevate the HIF-1 expression to an even higher extent than
single therapy, which could alter tumor cell behavior and
promote the aggression of cells. Therefore, it is important to
review the possible molecular effects of HT in considering its
application as an adjuvant therapy, as other groups have
reported that HIF-1 can also be up-regulated by radiotherapy
and chemotherapy [39-41]. Based on our study, IR820-PGMD
NPs could be used for HT applications without inducing the
adverse effects of HIF-1. The HT therapeutic effect might be
determined more by the temperature and the heating rate and
perhaps less by the total thermal dose. Due to the usage of laser/
NP HT we did not observe enhancement of HIF-1 and
VEGF expression, but an improved therapeutic outcome was
still achieved compared to incubator HT. Despite these
promising results for laser/NP HT, further studies have to
be performed to determine treatment parameters, such
as how to efficiently deliver these NPs and the timing for HT
treatment.
Conclusion
In summary, we successfully developed IR820-PGMD NPs,
which are promising as theranostic agents with multifunctional
imaging and HT capabilities. These NPs, when tested in vitro
and in vivo, are able to yield higher fluorescence intensity than
free IR820 24 h after incubation or 24 h after i.v. injection of
equivalent dye concentrations, allowing for longer imaging
collection times and potentially widening the window for HT
applications. We also proved in our study that the use of IR820-
PGMD NPs and laser/NP HT will neither activate ROS expres-
sion, nor induce HIF-1 and VEGF expression, which could
yield a beneficial therapeutic outcome. This study is an exten-
sion of the current knowledge of delivery of HT in NP form,
and we believe it will have a significant impact on the applica-
tion of nanotechnology on cancer imaging and therapy.
Experimental
Chemicals and cell-based assays
The following materials were purchased from Sigma-Aldrich
(St. Louis, MI): Malic acid, 1,12-dodecanedioic acid (DDA),
dimethylsulfoxide (DMSO > 99.9%, reagent grade), pluronic
F-127, Dulbecco phosphate-buffered saline (DPBS), phosphate
buffered saline (PBS), IR820, penicillin-streptomycin solution,
tetrahydrofuran (THF) and trypsin-EDTA. Glycerol was
purchased from MP Biomedical (MP Biomedical, LLC, Solon
OH). 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein
diacetate, acetyl ester (CM-H2DCFDA) was purchased from
Invitrogen, (Invitrogen, NY), human/mouse total HIF-1 alpha
cell-based ELISA and human VEGF quantikine ELISA kit were
purchased from R & D systems (R & D Systems, MN).
Synthesis and characterization of PGMD
polymer
This procedure has been previously described by our group
[24]. Briefly, a mixture of glycerol, DDA and malic acid
(7:3 DDA:malic acid; 1:1 glycerol:DDA/malic acid) was heated
to 120 °C for 48 h. Malic acid allows us to control the degree of
hydrophilicity and in turn the glass transition temperature (Tg).
Characterization was performed by differential scanning calori-
metry (for glass transition temperature) and gel permeation
chromatography (for molecular weight, based on a calibration
curve of polysterene standards).
Synthesis and characterization of IR820-
PGMD NPs
IR820-PGMD NPs were prepared by using an oil-in-water
emulsification solvent evaporation technique followed by
centrifugation at 5000 rpm for 5 min, and dialysis at MWCO
1000 Da to remove any free IR820 residue. After preparation,
the particles were freeze-dried and lyophilized for 48 h. To
measure the IR820-PGMD NP size distribution, 100 µL IR820-
PGMD NPs were resuspended in 3 mL deionized (DI) water.
Then, the solution was measured for average size, size distribu-
tion plot based on intensity plot, polydispersity, and zeta poten-
tial with a Malvern Zetasizer (Malvern Instruments, Worcester-
shire, United Kingdom). The size of the particles was measured
by determining a correlation function and fitting a polynomial
to the correlation function. We used the cumulant analysis as a
fitting model for the correlation function in our study. The
average particle size, polydispersity, and zeta potential were
determined from 10 different NP batches. The DLS intensity
plot was obtained from one batch of void PGMD NPs and
IR820-PGMD NPs. Scannning Electron Microscopy (SEM,
JEOL-JEM) was also used to characterize the NPs shape and
size. The loading of IR820 in NP's was evaluated by using a
Cary WinUV spectrophotometer (Varian/Agilent Technologies,
Switzerland).
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In vitro studies of NPs
Cancer cells MES-SA, Dx5, and SKOV3 were purchased from
American Type Culture Collection (Manassas, VA) along with
McCoy’s 5A medium and fetal bovine serum. Cell culture
supplies were purchased from Fisher Scientific (Pittsburg, PA),
and penicillin was purchased from Sigma-Aldrich. Cell
culture conditions were as described in our previous publica-
tion [24], with 1% penicillin and 10% fetal bovine serum
supplementation.
Subcellular localization of the NPs
SKOV-3 cells were plated in a 24-well tissue culture plate at
densities of 4 × 104 cells per well. After overnight incubation to
allow for attachment and confluence, we replaced the medium
with the test solutions, namely 5 µM free IR820 or 0.05 mg/mL
IR820-PGMD NPs (equivalent to 5 µM IR820). Plates were
kept at physiological temperature in the dark inside an incu-
bator. Subcellular localization of the IR820-PGMD NPs was
identified by incubating 5 µM Lysotracker Blue (Invitrogen,
NY) with cells for 10 min at the end of the experiment, fol-
lowed by 3 × wash with PBS, and fixation with 4% (vol/vol)
formaldehyde. Fluorescence images were obtained by using a
60 × water merged objective and a CCD camera, with fluores-
cence filters of λex = 775 nm, λem = 845 nm for IR820, and
λex = 355 nm, λem = 420 nm for LysoTracker Blue. After
processing to add pseudo color (IPLab, Qimaging, Canada), the
images were imported into Matlab (MathWorks, Massachusetts)
and analyzed to determine the intensity ratio R. First, the inten-
sity of each pixel was background-subtracted, and the region of
interest was defined as being composed of any pixels with
above-background intensity values (defined as an intensity of at
least 2 out of a 255 scale after background subtraction). The
ratio R was then determined by normalizing the total pixel
intensity of this region of interest to its total area.
HT treatment
Two different heating modes, namely (1) an incubator and (2) a
laser/NP HT delivery system, were used for in vitro studies.
Detailed descriptions of the heating systems and the tempera-
ture calibration for both heating modes were provided in our
previous paper [23]. Note that when incubator HT was used,
cells were incubated with the same concentration of IR820-
PGMD NPs as used in laser/NP HT in order to eliminate the
effect of NPs by themselves.
Cytotoxicity assessment
Cell viability after five different treatments (laser only, void
PGMD NPs w/ laser, IR820-PGMD NPs, IR820-PGMD NPs w/
laser, incubator HT w/ IR820-PGMD NPs) was measured
with the Sulforhodamine B colorimetric (SRB) assay 24 h
post-treatment, as previously described in our publications
[24,42]. The effect of each treatment on cell growth was
normalized to the growth of the control group, which did not
receive any treatment.
Cell-based assays for the detection of ROS,
HIF-1 and VEGF expression
Study of ROS expression
Intracellular ROS level was measured by using the fluorescent
dye CM-H2DCFDA, which is converted into a nonfluorescent
derivative (H2DCF) by cellular esterases after uptake by cells.
Then, H2DCF can be oxidized to highly fluorescent 2′,7′-
dichlorofluorescein (DCF) in the presence of ROS. After HT
(either 1 h incubator HT or 3 min laser HT), cells were washed
with PBS and collected by incubating with trypsin for 5 min.
The same number of cells were counted and incubated with
CM-H2DCFDA in the dark. After 30 min, cells were briefly
washed with PBS, and the intensity of DCF was measured by a
flow cytometer (BD Accuri C6, NJ).
Study of HIF-1 expression
To investigate HIF-1 expression in both incubator HT and laser/
NP HT, a human/mouse enzyme-linked immunosorbent assay
(ELISA) was used to detect the expression of HIF-1 by using
specific HIF-1 antigen. Basal level HIF-1 expression was iden-
tified in cells incubated at normal temperature (37°C). HIF-1
expression was measured immediately after HT by reading the
plate with a fluorescence plate reader (GENios, TECAN, CA)
with an excitation at 540 nm and an emission at 600 nm to
measure the amount of total HIF-1 in the cells. Then, the plate
was read with an excitation at 360 nm and an emission at
450 nm to measure the amount of total cytochrome c in the
cells. Finally, the HIF-1 amount was normalized to the amount
of cytochrome c and expressed as HIF-1 activity.
Study of VEGF expression
Cancer cell culture medium was collected 6 h after HT. After
centrifuging cell culture media for 10 min at 14000 rpm,
200 µL of supernatant was added into a 96-well plate provided
in a human quantikine VEGF ELISA kit. VEGF levels were
quantified following the kit protocol, and a sulforhodamine B
(SRB) assay (Invitrogen, NY) was used to determine the
amount of cellular protein in each well. Subsequently, the
measured VEGF amount was normalized to SRB value and the
calculated results were normalized to controls.
In vivo optical imaging
Animal studies were performed following the regulations of the
Institutional Animal Care and Use Committee. Twenty-four
Nd4 Swiss Webster mice (25–30 grams, 9 weeks old) were
purchased from Harlan (Indianapolis, IN), and randomly
distributed into 8 different experimental groups based on two
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factors: time elapsed between injection and data collection
(15 min, 30 min, 60 min, and 24 h), and solution injected
(0.2 mL of either free IR820 or IR820-PGMD NPs in PBS).
Injected solution concentration was matched to an IR820
dose of 0.24 mg/kg of body weight [43]. The in vivo biodis-
tribution of the NPs was recorded with a CCD camera
(Qimaging, Canada) coupled with a NIR filter (λex = 785 nm,
λem = 820 nm). Later, the images were processed with Matlab
to calculate the image fluorescence intensity ratio R as
described above.
Statistical analysis
Statistically significant (p < 0.05) differences in responses
between the treatment groups and control groups was analyzed
by ANOVA or t-test (SPSS, Chicago, Illinois).
Supporting Information
Supporting Information File 1
Additional experimental details.
[http://www.beilstein-journals.org/bjnano/content/
supplementary/2190-4286-5-35-S1.pdf]
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